Phase i dose-escalation study evaluating safety, tolerability and pharmacokinetics of MEDI-573, a dual IGF-I/II neutralizing antibody, in Japanese patients with advanced solid tumours

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 194-200

  Iguchi, Haruo ^a   Nishina, Tomohiro ^a   Nogami, Naoyuki ^a   Kozuki, Toshiyuki ^a   Yamagiwa, Yumiko ^a   Yagawa, Katsuro ^b  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^b ASTRAZENECA   (United Kingdom)

Author keywords

IGF II I inhibitor; MEDI 573; Monoclonal antibody; Novel antitumour agent; Phase I; Solid tumours

Indexed keywords

DUSIGITUMAB; ANTINEOPLASTIC AGENT; MEDI-573; NEUTRALIZING ANTIBODY; SOMATOMEDIN B; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; IMMUNOGENICITY; INFUSION RELATED REACTION; INSOMNIA; JAPANESE (PEOPLE); KERATITIS; LIMB PAIN; LIVER DISEASE; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; RASH; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TREATMENT OUTCOME; VOMITING; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; NEOPLASMS;

AGED; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 84922098787     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0170-x     Document Type: Article

References (10)

1. Zha J, Lackner MR (2010) Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 16:2512-2517
2. Arnaldez FI, Helman LJ (2012) Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am 26:527-viii
3. Ryan PD, Goss PE (2008) The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13:16-24
4. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6:1-12
5. Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA (2007) Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 56:343-357
6. Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS (2011) Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 71:1029-1040
7. Yuen JS, Macaulay VM (2008) Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 12:589-603
8. Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P (2014) Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors. Clin Cancer Res
9. Scagliotti GV, Novello S (2012) The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev 38:292-302
10. Chen HX, Sharon E (2013) IGF-1R as an anti-cancer target-trials and tribulations. Chin J Cancer 32:242-252